
Conference Coverage
about 2 hours ago
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1about 6 hours ago
Zelicapavir Shortens RSV Symptoms but Misses Primary End PointLatest Content

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE

Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1

Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria

Zelicapavir Shortens RSV Symptoms but Misses Primary End Point

FDA Approves Bepirovirsen, First Antisense Therapy for Chronic Hepatitis B

Shorts










Videos
Contagion Digital Edition









All News

In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.

The first animal model of neonatal sepsis to evaluate protection by maternal vaccination evidences transfer of immunity against virulent, often antibiotic-resistant Klebseilla pneumoniae.

The CHMP adopted a positive opinion on an extension of indication for AstraZeneca's H5N1 pandemic influenza vaccine at its October meeting.

The company, Family Farmstead Dairy, issued a raw cheddar recall over potential contamination with Shiga toxin-producing Escherichia coli (STEC) is happening across 7 states.

The guidelines issued by the Department of Health and Human Services (HHS) have been updated with recent, evidence-based consensus of The Panel for the Use of Antiretroviral Agents in Adults and Adolescents.

As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.

As of October 15, CDC reports 9235 confirmed cases and 4444 deaths in the Bundibugyo virus Ebola outbreak in the DRC, now the second-largest on record.

The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.

Serial bloodstream isolates from two critically ill London patients showed heteroresistance, CRZ1 escape mutations, and drug-induced polyploidy despite wild-type FKS1 and susceptible MICs.

Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.

Approximately 12% of all new cases of cancer worldwide in 2024 were attributable to an infection, with most of the infections preventable or treatable before cancer develops.

After 2 adults died of West Nile virus in central North Carolina this month, this FAQ explains how the mosquito-borne virus spreads, who faces the greatest risk of severe neuroinvasive disease, and how clinicians can diagnose, manage, and help prevent infection when no vaccine or antiviral treatment exists.

North Carolina health officials confirmed two West Nile virus deaths among adults in the central part of the state, where CDC data show 11 human cases this season.

A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.

The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.





















































































































































































